srfcure srfcure

393 posts   1443 followers   892 followings

Scleroderma Research Fdn.  America's leading nonprofit investor in medical research to find better treatments and a cure for scleroderma.

We need YOU to help us #spreadtheword that research is the key to putting an end to #scleroderma! Double tap, tag a friend in the comments, and include #spreadtheword to win a chance at a signed copy of "Dirty Daddy" by @bobsaget, our champion and Board Member. We'll be picking a winner soon! #researchisthekey #winachance #findacure

"SRF gives me hope that a cure will be found not only in time for me, but in time for all of us.” Read more about Jane’s inspiring story at the link in our bio!

We want to #SpreadTheWord that research is the KEY to putting an end to #scleroderma! Double tap, tag a friend in the comments, and include #SpreadTheWord to win a chance at a SIGNED COPY of “Dirty Daddy” by our champion, SRF Board Member Bob Saget. #ResearchIsTheKey #WinAChance #FindACure

For #NationalNonProfitDay, we're celebrating our wonderful Cure Crew – the volunteers who are at the heart of our efforts to spread awareness about #scleroderma. Double-tap to thank them!

@srfcure Board Member, Dr. Eric Kau, with Dr. Mark Nicolls, Professor and Division Chief of Pulmonary and Critical Care Medicine at last week's International Workshop on Scleroderma Research! Dr. Nicolls is a Principal Investigator of the clinical trial of Rituxan in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). PAH is a life-threatening complication of scleroderma with a three-year survival rate of approximately 75%. Patients with concomitant interstitial lung disease have poorer survival rates. Rituxan is a B-cell depleting therapy that has a track record of success in treating certain cancers. Dr. Nicolls is also a member of the NCSRC (Northern California Scleroderma Research Consortium), which is funded by the SRF. For more information about the Rituxan clinical trial, click the link in our bio and visit the News for Patients section on our website. #researchisthekey #collaborationisessential #scleroderma #srfcure

It is with great sadness that the SRF shares the passing of Dr. Andrew “Andy” M. Tager. Vibrant, kind, and generous, Andy sought to improve the quality of life for countless patients not only with his indomitable spirit, but through his passionate commitment to his scientific work as a physician and researcher. The SRF is proud to have sponsored work in the Tager lab over many years and partly with that support, Andy has been a major contributor to our understanding of fibroblast/myofibroblast behavior and fibrosis. Furthermore, he was highly regarded and recognized for his efforts that brought a greater understanding to pulmonary fibrosis and to potential treatments to those who suffer from diseases like scleroderma. He truly embodied the SRF belief that collaboration is essential, never missing an opportunity to seek and share knowledge. Our thoughts and prayers are with his wife Cynthia, his son Sam, and his extended family. His legacy will live on through all those he inspired. We will miss Andy deeply, but we are forever grateful for the opportunity to have worked with him and experience his endless enthusiasm, optimism, and joy.

A deceptively simple (but vital) #SRFpatientTip to remember.

Lung fibrosis is the root of one of #scleroderma’s most serious complications, which is why it’s a focus of the Northern California Scleroderma Research Consortium – an SRF-funded collaboration between and UCSF scientists! #researchisthekey #collaborationisessential #srfcure

This may look like a painting, but it’s actually an image of #scleroderma renal crisis, which is manageable if caught and treated early. Check out the SRF webinar series to learn more by visiting the link in our bio. #researchisthekey #srfcure

Another hugely successful International Workshop on Scleroderma Research concludes today! Sharing a picture from last night’s banquet at the beautiful Carnegie Museum Music Hall Foyer. We are SO proud to be a sponsor once again and look forward to the 2019 Workshop in Cambridge, England. #researchisthekey #collaborationisessential #scleroderma #srfcure

Day 3 of the 15th International Workshop on Scleroderma Research. Dr. Dinesh Khanna, Professor of Internal Medicine and Director of the Scleroderma Center at @umichmedicine and Dr. Luke Evnin, Chairman of @srfcure discuss ongoing clinical trials in scleroderma. Several presentations highlighted new therapeutic opportunities for patients. #researchisthekey #collaborationisessential #scleroderma #srfcure

Day 2 of the 15th International Workshop on Scleroderma Research! Board Member @deann_wright with Dr. Kathryn Torok, a pediatric rheumatologist from the University of Pittsburgh and a @srfcure funded investigator #researchisthekey #collaborationisessential #scleroderma #srfcure

Most Popular Instagram Hashtags